Guido Rassi, Executive Director of the European Medicines Agency EMA, said that the US Gilead Sciences Inc had received a preliminary license to use “Ramdesivir” against the COVID-19, Amerikayidzayn.com reports.
The European Medicines Agency (EMA) has already recommended the use of “Ramdesivir”, allowing the drug to be given to patients before it is fully approved.
EU law allows the drug to be sold for one year in the territory of the alliance before the publication of all the necessary data on its effectiveness and side effects.
In addition to “Ramdesivir”, Rassi noted that other COVID-19 treatments include monoclonal antibody drugs that can block the new coronavirus.
The outbreak of the virus has sparked widespread interest in “Ramdesivir” in a number of countries around the world, as there are currently no other approved treatments or vaccines against COVID-19.
